Melanoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Mahshid |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Melanoma}} | {{Melanoma}} | ||
{{CMG}} {{AE}} {{YD}}; {{SSK}} | {{CMG}} {{AE}} {{YD}}; {{SSK}}{{Sab}} | ||
==Overview== | ==Overview== | ||
Dynamic contrast-enhanced MRI (DCE-MRI), [[Positron emission tomography|positron emission tomography (PET) scan]], and Integrated <sup>18</sup>F-FDG PET/CT can be used during the [[Diagnosis|diagnostic process]] of melanoma. DCE-MRI has the potential to be an [[in vivo]] [[imaging]] technique that can predict and isolate the patient group prone to metastatic disease. Integrated <sup>18</sup>F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis. Positron emission tomography (PET) scan can help in diagnosing metastatic lesions. | |||
==Positron Emission Tomography (PET) Scan== | ==Dynamic contrast-enhanced MRI== | ||
*Dynamic contrast-enhanced MRI can reveal different contrast enhancement patterns in relation to microvasculature and the expression of angiogenetic factor such as vascular endothelial growth factor.<ref name="pmid22381901">{{cite journal |vauthors=Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK |title=Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=83 |issue=1 |pages=e121–7 |date=May 2012 |pmid=22381901 |doi=10.1016/j.ijrobp.2011.12.019 |url=}}</ref> | |||
*It can differentiate the tumor characterization between metastatic and non-metastatic melanoma by the K<sup>trans</sup> value.<ref name="pmid28448404">{{cite journal |vauthors=Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV |title=Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential |journal=J Comput Assist Tomogr |volume=41 |issue=5 |pages=823–827 |date=2017 |pmid=28448404 |doi=10.1097/RCT.0000000000000598 |url=}}</ref><ref name="pmid22381901">{{cite journal |vauthors=Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK |title=Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=83 |issue=1 |pages=e121–7 |date=May 2012 |pmid=22381901 |doi=10.1016/j.ijrobp.2011.12.019 |url=}}</ref> | |||
*DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease.<ref name="pmid28448404">{{cite journal |vauthors=Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV |title=Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential |journal=J Comput Assist Tomogr |volume=41 |issue=5 |pages=823–827 |date=2017 |pmid=28448404 |doi=10.1097/RCT.0000000000000598 |url=}}</ref> | |||
==Positron Emission Tomography (PET) Scan== | |||
*Chest PET scan may be considered for diagnosis of metastatic lesions in the following conditions:<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | *Chest PET scan may be considered for diagnosis of metastatic lesions in the following conditions:<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
:*For patients who have been diagnosed with stage IA-IV melanoma | :*For patients who have been diagnosed with stage IA-IV melanoma | ||
:*For secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years) | :*For secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years) | ||
==Integrated <sup>18</sup>F-FDG PET/CT== | |||
*Integrated <sup>18</sup>F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis.<ref name="pmid26204273">{{cite journal |vauthors=Perng P, Marcus C, Subramaniam RM |title=(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis |journal=AJR Am J Roentgenol |volume=205 |issue=2 |pages=259–70 |date=August 2015 |pmid=26204273 |doi=10.2214/AJR.14.13575 |url=}}</ref> | |||
==References== | ==References== | ||
Latest revision as of 19:18, 31 July 2019
|
Melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Melanoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Melanoma other imaging findings |
|
Risk calculators and risk factors for Melanoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
Dynamic contrast-enhanced MRI (DCE-MRI), positron emission tomography (PET) scan, and Integrated 18F-FDG PET/CT can be used during the diagnostic process of melanoma. DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease. Integrated 18F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis. Positron emission tomography (PET) scan can help in diagnosing metastatic lesions.
Dynamic contrast-enhanced MRI
- Dynamic contrast-enhanced MRI can reveal different contrast enhancement patterns in relation to microvasculature and the expression of angiogenetic factor such as vascular endothelial growth factor.[1]
- It can differentiate the tumor characterization between metastatic and non-metastatic melanoma by the Ktrans value.[2][1]
- DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease.[2]
Positron Emission Tomography (PET) Scan
- Chest PET scan may be considered for diagnosis of metastatic lesions in the following conditions:[3]
- For patients who have been diagnosed with stage IA-IV melanoma
- For secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years)
Integrated 18F-FDG PET/CT
- Integrated 18F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis.[4]
References
- ↑ 1.0 1.1 Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK (May 2012). "Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts". Int. J. Radiat. Oncol. Biol. Phys. 83 (1): e121–7. doi:10.1016/j.ijrobp.2011.12.019. PMID 22381901.
- ↑ 2.0 2.1 Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV (2017). "Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential". J Comput Assist Tomogr. 41 (5): 823–827. doi:10.1097/RCT.0000000000000598. PMID 28448404.
- ↑ Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.
- ↑ Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.